Taiwan Bio Therapeutics Co., Ltd.

Taiwan Bio Therapeutics Co., Ltd.

TTPEX:6892
26.70
TWD
-0.20
(-0.74%)
-4.97EPS
2.81BMarket Cap

Latest Stock Split

Dec 17, 2025

202:201

For every 201 shares held, investors received 202. The price per share adjusted from $27.75 to $27.61.

The split itself did not change the total investment value.

Use this split data in your app

Build with our data

Stock Split History

  1. Dec 17, 2025
    Before$27.75
    Split ratio202:201
    After$27.61
    Forward
  2. Apr 27, 2023
    Before$39.15
    Split ratio635:613
    After$37.79
    Forward

About Taiwan Bio Therapeutics Co., Ltd. stock splits

Taiwan Bio Therapeutics Co., Ltd. (TPEX:6892) operates in the Biotechnology industry.

Taiwan Bio Therapeutics Co., Ltd. company overview

When did Taiwan Bio Therapeutics Co., Ltd. stock split?

Taiwan Bio Therapeutics Co., Ltd.'s most recent stock split was on December 17, 2025. It was a 202-for-201 forward split, so shareholders received 202 shares for every 201 they held.

What is Taiwan Bio Therapeutics Co., Ltd.'s stock split history?

Taiwan Bio Therapeutics Co., Ltd. (TPEX:6892) has split its stock 2 times: a 635-for-613 split on April 27, 2023 and a 202-for-201 split on December 17, 2025.

How many times has Taiwan Bio Therapeutics Co., Ltd. stock split?

Taiwan Bio Therapeutics Co., Ltd. has split its stock 2 times. This history records 2 forward splits between April 27, 2023 and December 17, 2025.

What is a stock split?

A stock split divides each share into more shares and lowers the price per share by the same factor, so the total value of a holding does not change. In Taiwan Bio Therapeutics Co., Ltd.'s 202-for-201 split on December 17, 2025, every 201 shares became 202 shares.

Will Taiwan Bio Therapeutics Co., Ltd. split its stock again?

Taiwan Bio Therapeutics Co., Ltd. has not announced a new split in our records. Its most recent split was on December 17, 2025, less than a year ago. Companies announce splits in advance, and any new TPEX:6892 split will appear on this page.